Proglumide: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Proglumide}} | |||
== | == Proglumide == | ||
[[File:Proglumide_structure.svg|thumb|right|Chemical structure of Proglumide]] | |||
'''Proglumide''' is a drug that was originally developed as a [[cholecystokinin]] (CCK) antagonist. It has been used in the treatment of [[peptic ulcers]] and other gastrointestinal disorders. Proglumide works by inhibiting the action of CCK, a hormone that stimulates the secretion of gastric acid and the contraction of the gallbladder. | |||
Proglumide | == Mechanism of Action == | ||
Proglumide acts as a competitive antagonist at the CCK receptors, specifically the CCK-A and CCK-B subtypes. By blocking these receptors, proglumide reduces the secretion of gastric acid and decreases gastrointestinal motility. This action helps in alleviating symptoms associated with peptic ulcers and other related conditions. | |||
== | == Clinical Uses == | ||
Proglumide has been used primarily in the management of [[peptic ulcer disease]]. It helps in reducing gastric acid secretion and provides symptomatic relief. Although its use has declined with the advent of more effective treatments such as [[proton pump inhibitors]] and [[H2 receptor antagonists]], proglumide is still of interest in research settings. | |||
== Research and Other Uses == | |||
In addition to its gastrointestinal applications, proglumide has been studied for its potential effects on [[pain management]]. It has been shown to enhance the analgesic effects of [[opioids]], potentially allowing for lower doses of opioids to be used in pain control. This property makes proglumide a subject of interest in the field of [[pain management]] and [[opioid]] research. | |||
== | == Side Effects == | ||
The side effects of proglumide are generally mild and may include [[nausea]], [[diarrhea]], and [[dizziness]]. As with any medication, it is important to use proglumide under the guidance of a healthcare professional. | |||
== Related Pages == | |||
* [[Cholecystokinin]] | |||
* [[Peptic ulcer disease]] | |||
* [[Gastric acid]] | |||
* [[Opioid]] | |||
* [[Pain management]] | |||
[[Category:Pharmacology]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Analgesics]] | |||
[[Category: | |||
[[Category: | |||
[[Category: | |||
Latest revision as of 11:22, 15 February 2025
Proglumide[edit]
Proglumide is a drug that was originally developed as a cholecystokinin (CCK) antagonist. It has been used in the treatment of peptic ulcers and other gastrointestinal disorders. Proglumide works by inhibiting the action of CCK, a hormone that stimulates the secretion of gastric acid and the contraction of the gallbladder.
Mechanism of Action[edit]
Proglumide acts as a competitive antagonist at the CCK receptors, specifically the CCK-A and CCK-B subtypes. By blocking these receptors, proglumide reduces the secretion of gastric acid and decreases gastrointestinal motility. This action helps in alleviating symptoms associated with peptic ulcers and other related conditions.
Clinical Uses[edit]
Proglumide has been used primarily in the management of peptic ulcer disease. It helps in reducing gastric acid secretion and provides symptomatic relief. Although its use has declined with the advent of more effective treatments such as proton pump inhibitors and H2 receptor antagonists, proglumide is still of interest in research settings.
Research and Other Uses[edit]
In addition to its gastrointestinal applications, proglumide has been studied for its potential effects on pain management. It has been shown to enhance the analgesic effects of opioids, potentially allowing for lower doses of opioids to be used in pain control. This property makes proglumide a subject of interest in the field of pain management and opioid research.
Side Effects[edit]
The side effects of proglumide are generally mild and may include nausea, diarrhea, and dizziness. As with any medication, it is important to use proglumide under the guidance of a healthcare professional.
